ProMIS Neurosciences Current ratio
Was ist das Current ratio von ProMIS Neurosciences?
Current ratio von ProMIS Neurosciences, Inc. ist 19.07
Was ist die Definition von Current ratio?
Das derzeitige Verhältnis ist ein Liquiditätsgrad das misst, ob ein Unternehmen über ausreichende Ressourcen verfügt, um seine kurzfristigen Verpflichtungen zu erfüllen.
The current ratio is an indication of a company's liquidity and measures the capability to meet a company's short-term obligations. It compares a firm's current assets to its current liabilities, and is expressed as current assets divided by current liabilities. The ratio is only useful when two companies are compared within industry because inter industry business operations differ substantially. To determine liquidity, the current ratio is not as helpful as the quick ratio, because it includes all those assets that may not be easily liquidated, like prepaid expenses and inventory.
Acceptable current ratios vary from industry to industry. In many cases an investor would consider a high current ratio to be better than a low current ratio, because a high current ratio indicates that the company is more likely to pay the investor back. Large current ratios are not always a good sign for investors. If the company's current ratio is too high it may indicate that the company is not efficiently using its current assets or its short-term financing facilities. If current liabilities exceed current assets the current ratio will be less than 1. A current ratio of less than 1 indicates that the company may have problems meeting its short-term obligations.
Some types of businesses can operate with a current ratio of less than one however. If inventory turns into cash much more rapidly than the accounts payable become due, then the firm's current ratio can comfortably remain less than one. Inventory is valued at the cost of acquiring it and the firm intends to sell the inventory for more than this cost. The sale will therefore generate substantially more cash than the value of inventory on the balance sheet. Low current ratios can also be justified for businesses that can collect cash from customers long before they need to pay their suppliers.
Current ratio von Unternehmen in Health Care Sektor auf OTC im Vergleich zu ProMIS Neurosciences
Was macht ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Unternehmen mit current ratio ähnlich ProMIS Neurosciences
- Stuhini Exploration hat Current ratio von 18.95
- US Masters Residential Property Fund hat Current ratio von 19.00
- Marenica hat Current ratio von 19.01
- Atea Pharmaceuticals hat Current ratio von 19.02
- Middle Island Resources hat Current ratio von 19.04
- Regulus Therapeutics Inc hat Current ratio von 19.06
- ProMIS Neurosciences hat Current ratio von 19.07
- Summit Therapeutics Inc hat Current ratio von 19.07
- Barings Participation Investors hat Current ratio von 19.07
- Uravan Minerals hat Current ratio von 19.08
- Danakali hat Current ratio von 19.10
- POCML 6 hat Current ratio von 19.12
- Beijing Baolande Software hat Current ratio von 19.13